Biogen Management
Management criteria checks 4/4
Biogen's CEO is Chris Viehbacher, appointed in Nov 2022, has a tenure of 2.08 years. total yearly compensation is $4.07M, comprised of 39.3% salary and 60.7% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth €1.00M. The average tenure of the management team and the board of directors is 4.6 years and 4.5 years respectively.
Key information
Chris Viehbacher
Chief executive officer
US$4.1m
Total compensation
| CEO salary percentage | 39.3% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.005% |
| Management average tenure | 4.6yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$4m | US$2m | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$3b |
| Mar 31 2023 | n/a | n/a | US$3b |
| Dec 31 2022 | US$30m | US$154k | US$3b |
Compensation vs Market: Chris's total compensation ($USD4.07M) is about average for companies of similar size in the Austrian market ($USD4.40M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Viehbacher (63 yo)
2.1yrs
Tenure
US$4,069,913
Compensation
Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$4.07m | 0.0048% € 1.0m | |
| Executive VP & CFO | 4.3yrs | US$7.17m | 0.013% € 2.8m | |
| Head of Pharmaceutical Operations & Technology | 2.9yrs | US$5.71m | 0.0066% € 1.4m | |
| Executive VP & Chief Legal Officer | 18.9yrs | US$6.70m | 0.035% € 7.4m | |
| Head of Global Product Strategy & Commercialization | 3.9yrs | US$5.45m | 0.0067% € 1.4m | |
| Senior VP & Chief Accounting Officer | 6.1yrs | no data | 0.0044% € 918.0k | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Communication Officer & Head of Corporate Affairs | 4.9yrs | no data | no data | |
| Executive VP & Head of Corporate Development | 1.7yrs | no data | 0.00045% € 93.9k | |
| Executive VP & Chief Human Resources Officer | 7.4yrs | US$5.08m | 0.0093% € 1.9m | |
| President & Head of North America | 7.4yrs | no data | no data | |
| Head of Biotherapeutics & Medicinal Sciences | 7.4yrs | no data | no data |
4.6yrs
Average Tenure
58yo
Average Age
Experienced Management: BIIB's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$4.07m | 0.0048% € 1.0m | |
| Independent Director | 14.8yrs | US$435.32k | 0.013% € 2.7m | |
| Independent Director | 5.5yrs | US$425.73k | 0.0044% € 928.4k | |
| Independent Chair of the Board | 14.9yrs | US$646.13k | 0.017% € 3.6m | |
| Independent Director | 14.8yrs | US$418.02k | 0.014% € 3.0m | |
| Independent Director | 3.5yrs | US$412.90k | 0.0031% € 636.3k | |
| Directors | less than a year | no data | no data | |
| Independent Director | less than a year | no data | 0.00092% € 191.9k | |
| Independent Director | 5.5yrs | US$433.23k | 0.0051% € 1.1m | |
| Independent Director | 1.5yrs | US$334.53k | 0.0019% € 394.3k |
4.5yrs
Average Tenure
65yo
Average Age
Experienced Board: BIIB's board of directors are considered experienced (4.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 02:45 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biogen Inc. is covered by 74 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Steven Chesney | Atlantic Equities LLP |
| Brian Skorney | Baird |